EBITDA: Income before interest, taxes, depreciation and amortization.
4D Molecular Therapeutics, Inc. (FDMT) had EBITDA of $-159.59M for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
$85.21M |
|
$-140.11M |
|
-- |
|
$85.21M |
|
$244.76M |
|
$-159.55M |
|
$19.44M |
|
$-140.11M |
|
$-140.11M |
|
$-140.11M |
|
$-140.11M |
|
$-140.11M |
|
$-140.11M |
|
$-159.55M |
|
|
EBITDA |
$-159.59M |
57.93M |
|
57.93M |
|
$-2.42 |
|
$-2.42 |
|
| Balance Sheet Financials | |
$413.13M |
|
$14.87M |
|
$153.58M |
|
$566.71M |
|
$43.98M |
|
-- |
|
$17.06M |
|
$61.05M |
|
$505.66M |
|
$505.66M |
|
$505.66M |
|
57.61M |
|
| Cash Flow Statement Financials | |
$-109.08M |
|
$-92.97M |
|
$112.96M |
|
$149.34M |
|
$60.24M |
|
$-89.09M |
|
$22.02M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
9.39 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
-187.24% |
|
-187.24% |
|
-187.29% |
|
-164.43% |
|
-164.43% |
|
$-109.62M |
|
-- |
|
-- |
|
-- |
|
0.15 |
|
-- |
|
-- |
|
-- |
|
-27.71% |
|
-27.71% |
|
-24.72% |
|
-27.71% |
|
$8.78 |
|
$-1.89 |
|
$-1.88 |
|